Aytu BioPharma, Inc. (LON:0A8M)

Aytu BioPharma Statistics

Total Valuation

Aytu BioPharma has a market cap or net worth of GBP 20.53 million. The enterprise value is 17.40 million.

Market Cap	20.53M
Enterprise Value	17.40M

Important Dates

The next estimated earnings date is Thursday, February 12, 2026.

Earnings Date	Feb 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	6.17M
Shares Outstanding	n/a
Shares Change (YoY)	+25.31%
Shares Change (QoQ)	+186.78%
Owned by Insiders (%)	5.41%
Owned by Institutions (%)	9.84%
Float	7.04M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.43
PB Ratio	1.19
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 3.59, with an EV/FCF ratio of -16.05.

EV / Earnings	-1.79
EV / Sales	0.37
EV / EBITDA	3.59
EV / EBIT	19.92
EV / FCF	-16.05

Financial Position

The company has a current ratio of 1.23, with a Debt / Equity ratio of 1.23.

Current Ratio	1.23
Quick Ratio	1.00
Debt / Equity	1.23
Debt / EBITDA	4.34
Debt / FCF	-19.49
Interest Coverage	0.37

Financial Efficiency

Return on equity (ROE) is -50.23% and return on invested capital (ROIC) is 1.48%.

Return on Equity (ROE)	-50.23%
Return on Assets (ROA)	0.61%
Return on Invested Capital (ROIC)	1.48%
Return on Capital Employed (ROCE)	2.00%
Revenue Per Employee	570,916
Profits Per Employee	-117,157
Employee Count	83
Asset Turnover	0.53
Inventory Turnover	1.89

Taxes

In the past 12 months, Aytu BioPharma has paid 23,806 in taxes.

Income Tax	23,806
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -34.72% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-34.72%
50-Day Moving Average	1.61
200-Day Moving Average	2.41
Relative Strength Index (RSI)	71.86
Average Volume (20 Days)	2,207

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.15

Income Statement

In the last 12 months, Aytu BioPharma had revenue of GBP 47.39 million and -9.72 million in losses. Loss per share was -1.43.

Revenue	47.39M
Gross Profit	32.01M
Operating Income	877,105
Pretax Income	-9.88M
Net Income	-9.72M
EBITDA	4.48M
EBIT	877,105
Loss Per Share	-1.43

Balance Sheet

The company has 24.27 million in cash and 21.13 million in debt, with a net cash position of 3.15 million.

Cash & Cash Equivalents	24.27M
Total Debt	21.13M
Net Cash	3.15M
Net Cash Per Share	n/a
Equity (Book Value)	17.24M
Book Value Per Share	1.74
Working Capital	11.25M

Cash Flow

In the last 12 months, operating cash flow was -1.02 million and capital expenditures -68,442, giving a free cash flow of -1.08 million.

Operating Cash Flow	-1.02M
Capital Expenditures	-68,442
Free Cash Flow	-1.08M
FCF Per Share	n/a

Margins

Gross margin is 67.56%, with operating and profit margins of 1.85% and -20.52%.

Gross Margin	67.56%
Operating Margin	1.85%
Pretax Margin	-20.85%
Profit Margin	-20.52%
EBITDA Margin	9.46%
EBIT Margin	1.85%
FCF Margin	n/a

Dividends & Yields

Aytu BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-25.31%
Shareholder Yield	-25.31%
Earnings Yield	-47.37%
FCF Yield	-5.28%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on January 6, 2023. It was a reverse split with a ratio of 0.05.

Last Split Date	Jan 6, 2023
Split Type	Reverse
Split Ratio	0.05

Scores

Aytu BioPharma has an Altman Z-Score of -2.95 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.95
Piotroski F-Score	4